This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sommerschild, H. T. Articles by Kirkebøen, K. A. Search for Related Content PubMed PubMed Citation Articles by Sommerschild, H. T. Articles by Kirkebøen, K. A.

(Circulation. 1997;96:3094-3103.)
© 1997 American Heart Association, Inc.

Articles

Importance of Endogenous Adenosine During Ischemia and Reperfusion in Neonatal Porcine Hearts

Hilchen T. Sommerschild, MD; Frank Grund, MD; Jon Offstad, MD, PhD; Per Jynge, MD, PhD; Arnfinn Ilebekk, MD, PhD; ; Knut A. Kirkebøen, MD, PhD

From the University of Oslo, Institute for Experimental Medical Research (H.T.S., F.G., J.O., A.I., K.A.K.) and Department of Anesthesia (K.A.K.), Ullevål Hospital, Oslo, and Institute for Physiology and Biomedical Techniques, Medical Technical Center, Trondheim (P.J.), Norway.

Background Adenosine has several potentially cardioprotective effects. We hypothesized that the effects of endogenous adenosine vary with degree of ischemia and that elevating endogenous levels is protective.

Methods and Results Isolated blood-perfused piglet hearts underwent 120 minutes of low-flow ischemia (10% flow) or 90 minutes of zero-flow ischemia, all with 60 minutes of reperfusion. Hearts were treated with either saline, the adenosine receptor blocker 8-sulfophenyltheophylline (8SPT, 300 µmol · L^-1), or the nucleoside transport inhibitor draflazine (1 µmol · L^-1). In separate groups, biopsies were obtained before and at the end of ischemia. Compared with saline, 8SPT did not significantly alter functional recovery in either protocol. Draflazine significantly improved percent recovery of left ventricular systolic pressure both in the low-flow protocol (92±3% versus 75±2% [saline] and 73±3% [8SPT], P<.001 for both) and in the zero-flow protocol (76±3% versus 59±4% [saline] and 46±9% [8SPT], P<.05 for both). In the zero-flow protocol, draflazine also significantly reduced ischemic contracture and release of creatine kinase. Tissue adenosine at the end of ischemia was elevated by draflazine compared with saline-treated hearts: after low-flow ischemia to 0.10±0.05 versus 0.00±0.00 µmol · g^-1 dry wt (P<.05) and after zero-flow ischemia to 1.73±0.82 versus 0.15±0.03 µmol · g^-1 dry wt (P<.05).

Conclusions In neonatal porcine hearts, endogenous adenosine produced during ischemia does not influence ischemic injury or functional recovery. Elevating endogenous adenosine by draflazine elicits cardioprotection in both low-flow and zero-flow conditions.

Key Words: adenosine • infarction • ischemia • myocardium • reperfusion

This article has been cited by other articles:

				N. Varma, J. P. Morgan, and C. S. Apstein Mechanisms underlying ischemic diastolic dysfunction: relation between rigor, calcium homeostasis, and relaxation rate Am J Physiol Heart Circ Physiol, March 1, 2003; 284(3): H758 - H771. [Abstract] [Full Text] [PDF]

				C. M. Hohl AMP deaminase in piglet cardiac myocytes: effect on nucleotide metabolism during ischemia Am J Physiol Heart Circ Physiol, May 1, 1999; 276(5): H1502 - H1510. [Abstract] [Full Text] [PDF]